Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 6/2018

01-11-2018 | Review

IgA nephropathy: clearance kinetics of IgA-containing immune complexes

Authors: Ann Chen, Sung-Sen Yang, Tsai-Jung Lin, Shuk-Man Ka

Published in: Seminars in Immunopathology | Issue 6/2018

Login to get access

Abstract

IgA nephropathy (IgAN) is associated predominantly IgA deposition in the affected glomeruli and has been shown to be the most common glomerular disorder among young people in the world. Although the exact pathogenic mechanism underlying IgAN remains largely unknown, circulating IgA-containing immune complexes (IgA ICs) is considered to play a major role in initiating the development and evolution of the renal disorder. In this review article, we discuss the fundamental mechanisms of clearance kinetics of IgA ICs and related issues, covering the following: (1) role of circulating IgA ICs in the pathogenesis of IgAN and (2) elimination of IgA ICs from the body, with emphasis of the role of the liver and Fc receptors in immune cells.
Literature
1.
Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22(10):1795–1803CrossRef
2.
Kiryluk K, Novak J (2014) The genetics and immunobiology of IgA nephropathy. J Clin Invest 124(6):2325–2332CrossRef
3.
Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA (2015) New insights into the pathogenesis of IgA nephropathy. Kidney Dis (Basel) 1(1):8–18 Epub 2015 May 1CrossRef
4.
Salvadori M, Rosso G (2015) Update on immunoglobulin a nephropathy. Part I: Pathophysiology World J Nephrol 4(4):455–467PubMed
5.
Allen AC, Willis FR, Beattie TJ, Feehally J (1998) Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 13(4):930–934CrossRef
6.
Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000;191(11):1999–2009
7.
Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67(2):504–513CrossRef
8.
Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA, Novak J (2016) The origin and activities of IgA1-containing immune complexes in IgA nephropathy. Front Immunol 7:117CrossRef
9.
Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12(4):677–686 ReviewCrossRef
10.
Canetta PA, Kiryluk K, Appel GB (2014) Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol 9(3):617–625 ReviewCrossRef
11.
Moreno JA, Martín-Cleary C, Gutiérrez E, Toldos O, Blanco-Colio LM, Praga M, Ortiz A, Egido J (2012) AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 7(1):175–184 ReviewCrossRef
12.
Floege J, Eitner F (2011) Current therapy for IgA nephropathy. J Am Soc Nephrol 22(10):1785–1794 ReviewCrossRef
13.
Ballardie FW (2007) Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol 18(11):2806–2809 ReviewCrossRef
14.
Tumlin JA, Madaio MP, Hennigar R (2007) Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2(5):1054–1061 ReviewCrossRef
15.
Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J (2017) Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy. Kidney Int Rep 2(6):1194–1207CrossRef
16.
Nagai K, Tominaga T, Ueda S, Shibata E, Tamaki M, Matsuura M, Kishi S, Murakami T, Moriya T, Abe H, Doi T (2017) Mesangial cell mammalian target of rapamycin complex 1 activation results in mesangial expansion. J Am Soc Nephrol 28(10):2879–2885CrossRef
17.
Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13(2):e1006609CrossRef
18.
Mirfazeli ES, Marashi SA, Kalantari S (2016) In silico prediction of specific pathways that regulate mesangial cell proliferation in IgA nephropathy. Med Hypotheses 97:38–45CrossRef
19.
Shen P, Shen J, Sun C, Yang X, He L (2016) A system biology approach to understanding the molecular mechanisms of Gubentongluo decoction acting on IgA nephropathy. BMC Complement Altern Med 16(1):312CrossRef
20.
Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, Julian BA, Novak J (2007) Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 44(10):2598–2604CrossRef
21.
Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43(4):321–327CrossRef
22.
Xu L, Li B, Huang M, Xie K, Li D, Li Y, Gu H, Fang J (2016 Jul 20) Critical role of Kupffer cell CD89 expression in experimental IgA nephropathy. PLoS One 11(7):e0159426CrossRef
23.
Rifai A, Mannik M (1983) Clearance kinetics and fate of mouse IgA immune complexes prepared with monomeric or dimeric IgA. J Immunol 130(4):1826–1832PubMed
24.
Rifai A, Mannik M (1983) The clearance kinetics and hepatic localization of IgA-immune complexes in mice. Ann N Y Acad Sci 409(1):861–863CrossRef
25.
Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol 1996;16(4):423–440
26.
Grossetête B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC (1998) Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 53(5):1321–1335CrossRef
27.
Emancipator SN, Gallo GR, Razaboni R, Lamm ME (1983) Experimental cholestasis promotes the deposition of glomerular IgA immune complexes. Am J Pathol 113(1):19–26PubMedPubMedCentral
28.
Gormly AA, Smith PS, Seymour AE, Clarkson AR, Woodroffe AJ (1981) IgA glomerular deposits in experimental cirrhosis. Am J Pathol 104(1):50–54PubMedPubMedCentral
29.
Hogg R, Silva F (1987) IgA nephropathy in children. In: Clarkson A (ed) IgA nephropathy. Martinus Nijhoff, Boston, pp 16–38CrossRef
30.
Haakenstad AO, Mannik M (1974) Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 112(5):193919–193948
31.
Arend WP, Mannik M (1971) Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. J Immunol 107(1):63–75PubMed
32.
Rifai A, Small P Jr, Ayoub EM (1984) Experimental IgA nephropathy. Factors governing the persistence of IgA-antigen complexes in the circulation of mice. Contrib Nephrol 40:37–44CrossRef
33.
Melvin T, Burke B, Michael AF, Kim Y (1983) Experimental IgA nephropathy in bile duct ligated rats. Clin Immunol Immunopathol 27(3):369–377CrossRef
34.
Egido J, Gonzalez E, Gonzalez Cabrero J, de Nicolas R, Herrero-Beaumont G, Sancho J. The role of circulating immune complexes and the liver in the development of IgA nephropathy in mice. Semin Nephrol 1987;7(4):289–293
35.
Chen A, Ding SL, Sheu LF, Song YB, Shieh SD, Shaio MF, Chou WY, Ho YS (1994) Experimental IgA nephropathy. Enhanced deposition of glomerular IgA immune complex in proteinuric states. Lab Investig 70(5):639–647PubMed
36.
Sato M, Ideura T, Koshikawa S (1986) Experimental IgA nephropathy in mice. Lab Investig 54(4):377–3784PubMed
37.
Benacerraf B, Sebestyen M, Cooper NS (1959) The clearance of antigen antibody complexes from the blood by the reticuloendothelial system. J Immunol 82(2):131–137PubMed
38.
Stewart WW, Kerr MA (1990) The specificity of the human neutrophil IgA receptor (Fc alpha R) determined by measurement of chemiluminescence induced by serum or secretory IgA1 or IgA2. Immunology 71(3):328–334PubMedPubMedCentral
39.
Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 2011;4(6):612–624. ReviewCrossRef
40.
van Dijk TB, Bracke M, Caldenhoven E, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP. Cloning and characterization of Fc alpha Rb, a novel Fc alpha receptor (CD89) isoform expressed in eosinophils and neutrophils. Blood 1996;88(11):4229–4238
41.
Yin N, Peng M, Xing Y, Zhang W (2007) Intracellular pools of FcalphaR (CD89) in human neutrophils are localized in tertiary granules and secretory vesicles, and two FcalphaR isoforms are found in tertiary granules. J Leukoc Biol 82(3):551–558CrossRef
42.
Strober W, Hague NE, Lum LG, Henkart PA (1978) IgA-Fc receptors on mouse lymphoid cells. J Immunol 121(6):2440–2445PubMed
43.
Rifai A, Mannik M (1984) Clearance of circulating IgA immune complexes is mediated by a specific receptor on Kupffer cells in mice. J Exp Med 160(1):125–137CrossRef
44.
Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177–204
45.
Patry C, Sibille Y, Lehuen A, Monteiro RC (1996) Identification of Fc alpha receptor (CD89) isoforms generated by alternative splicing that are differentially expressed between blood monocytes and alveolar macrophages. J Immunol 156(11):4442–4448PubMed
46.
van Zandbergen G, van Kooten C, Mohamad NK, Reterink TJ, de Fijter JW, van de Winkel JG, Daha MR. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 1998;13(12):3058–3064
47.
van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, van Hattum J, Kuiper J, van de Winkel JG. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000;6(6):68068–68065
48.
Bogers WM, Stad RK, Janssen DJ, Prins FA, van Rooijen N, van Es LA, Daha MR. Kupffer cell depletion in vivo results in clearance of large-sized IgA aggregates in rats by liver endothelial cells. Clin Exp Immunol 1991;85(1):128–136CrossRef
Metadata
Title
IgA nephropathy: clearance kinetics of IgA-containing immune complexes
Authors
Ann Chen
Sung-Sen Yang
Tsai-Jung Lin
Shuk-Man Ka
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 6/2018
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-018-0708-7

Other articles of this Issue 6/2018

Seminars in Immunopathology 6/2018 Go to the issue

Review

Pivotal role of innate myeloid cells in cerebral post-ischemic sterile inflammation

Review

A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM)

Review

Picket-fences in the plasma membrane: functions in immune cells and phagocytosis

Introduction

Homage to Mechnikov – the phagocytic system: past and present

Review

Acute and chronic phagocyte determinants of cardiac allograft vasculopathy

Review

Efferocytosis in the tumor microenvironment
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits